学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

池田圭吾（イケダケイゴ）

研究テーマ	リウマチ性疾患におけるバイオマーカー、新規治療法の探索、臨床情報管理の効率化
研究業績（論文）	「英文原著」 1. Suzuki S, Taniguchi Y, Otani T, Nakazawa T, Ikeda K, Morimoto S. Infectious dissecting aortic aneurysm due to Streptococcus pseudopneumoniae mimicked large vessel vasculitis. Clin Case Rep Int. 2023; 7: 1545. 2. Dankers W, Northcott M, Bennett T, D’Cruz A, Sherlock R, Gearing LJ, Hertzog P, Russ B, Miceli I, Scheer S, Fujishiro M, Hayakawa K, Ikeda K, Morand EF, Jones SA. Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ). Front. Immunol. 2022 Nov 23. 3. Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I. Exposure of female NZBWF1 mice to imiquimod induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol. 2022 Feb 2. 4. Suzuki S, Ikeda K, Yamaji K, Tamura N, Morimoto S. Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review. Mod Rheumatol Case Rep. 2021 Feb 9. 5. Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Kataoka Y, Suzuki S, Ikeda K, Takamori K, Yamaji K, Tamura N. Metformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. 2021 Jul-Aug; 39(4): 763-768. 6. Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S. Complication of COVID-19 during remission induction therapy against anti-MDA5 antibody positive dermatomyositis. Rheumatol Adv Pract. 2020 Nov 17. rkaa068. 7. Yoshida Y, Hayakawa K, Fujishiro M, Ikeda K, Tsushima H, Hirai T, Kawasaki M, Tominaga M, Suga Y, Takamori K, Sekigawa I, Morimoto S. Social defeat stress exacerbates atopic dermatitis through downregulation of DNA methyltransferase 1 and upregulation of C–C motif chemokine receptor 7 in skin dendritic cells. Biochem Biophys Res Commun. 2020 Sep; 529(4): 1073-1079. 8. Suzuki S, Ogiwara K, Nishi T, Sakuma S, Akira M, Iwasaki M, Honda D, Takahara H, Ikeda K, Yamaji K, Tamura N, Rinno H, Morimoto S. A Case of MPO-ANCA Positive Systemic Lupus Erythematosus Developed into Acute Kidney Injury. Arch Clin Med Case Rep. 2019 Sep; 3(6): 560-566. 9. Hayakawa K, Kawasaki M, Hirai T, Yoshida Y, Tsushima H, Fujishiro M, Ikeda K, Morimoto S, Takamori K, Sekigawa I. MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-κB Signaling. Int. J. Mol. Sci. 2019 Feb; 20(4), 809. 10. Ikeda K, Sekiguchi N, Hirai T, Tanji K, Zushi A, Inoue M, Takasago M, Komatsu T, Morimoto S, Yamaji K, Takamori K, Tamura N, Sekigawa I. Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patients. Musculoskeletal Care. 2018 Jun 28. 11. Niimi N, Miyashita T, Tanji K, Hirai T, Watanabe K, Ikeda K, Morimoto S, Sekigawa I. Aortic Aneurysm as a Complication of Granulomatosis with Polyangiitis Successfully Treated with Prednisolone and Cyclophosphamide: A Case Report and Review of the Literature. Case Rep Rheumatol. 2018 Jun 5. 12. Hayakawa K, Ikeda K, Fujishiro M, Yoshida Y, Hirai T, Tsushima H, Miyashita T, Morimoto S, Suga Y, Takamori K, Ogawa H, Sekigawa I. Connective tissue growth factor neutralization aggravates the psoriasis skin lesion: the analysis of psoriasis model mice and patients. Ann Dermatol. 2018 Feb; 30(1): 47-53. 13. Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, Morimoto S, Yamaji K, Takasaki Y, Takamori K, Tamura N, Sekigawa I. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen. 2018 Jan 8; 38:1. 14. Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S, Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017 Aug 23;18(1):42. 15. Tsushima H, Morimoto S, Fujishiro M, Yoshida Y, Hayakawa K, Hirai T, Miyashita T, Ikeda K, Yamaji K, Takamori K, Takasaki Y, Sekigawa I, Tamura N. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity. 2017 Jul 6:1-7. 16. Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Intern Med. 2017 May; 56(10): 1147-1152. 17. Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M, Tamura N, Sekigawa I. Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int. 2017 Aug; 37(8): 1395-1399. 18. Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I. The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study. Clin Rheumatol. 2017 Jan; 36(1): 51-58. 19. Uomori K, Nozawa K, Ikeda K, Doe K, Yamada Y, Yamaguchi A, Fujishiro M, Kawasaki M, Morimoto S, Takamori K, Sekigawa I, Chan EKL, Takasaki Y. A re-evaluation of anti-NA-14 antibodies in patients with primary Sjögren's syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14. Autoimmunity. 2016 Jun 21: 1-10. 20. Miyashita T, Morimoto S, Fujishiro M, Hayakawa K, Suzuki S, Ikeda K, Miyazawa K, Morioka M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y. Inhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis. Autoimmunity. 2015 Nov 19: 1-6. 21. Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, Sekigawa I, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N, Noguchi M. Epstein-Barr Virus-Positive Multiple Myeloma Developing After Immunosuppressant Therapy for Rheumatoid Arthritis − A Case Report and Literature Review. Int J Clin Exp Pathol. 2015 Feb 1; 8(2): 2090-102. 22. Suzuki S, Morimoto S, Fujishiro M, Kawasaki M, Hayakawa K, Miyashita T, Ikeda K, Miyazawa K, Yanagida M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis. Autoimmunity. 2014 Oct 29: 1-8. 23. Ikeda K, Takasaki Y, Sekigawa I. Rapid onset of small intestinal perforation after successful steroid treatment in eosinophilic granulomatosis with polyangiitis. Mod Rheumatol. 2014 Aug 11: 1-3. 24. Doe K, Nozawa K, Hiruma K, Yamada Y, Matsuki Y, Nakano S, Ogasawara M, Nakano H, Ikeda T, Ikegami T, Fujishiro M, Kawasaki M, Ikeda K, Amano H, Morimoto S, Ogawa H, Takamori K, Sekigawa I, Takasaki Y. Antibody against chromatin assembly factor-1 is a novel autoantibody specifically recognized in systemic lupus erythematosus. Lupus. 2014 Sep; 23(10): 1031-41. 25. Yanagida M, Kawasaki M, Fujishiro M, Miura M, Ikeda K, Nozawa K, Kaneko H, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Sekigawa I. Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody. Biomed Res Int. 2013 (2013), 607137. 26. Nozawa K, Fujishiro M, Kawasaki M, Yamaguchi A, Ikeda K, Morimoto S, Iwabuchi K, Yanagida M, Ichinose S, Morioka M, Ogawa H, Takamori K, Takasaki Y, Sekigawa I. Inhibition of connective tissue growth factor ameliorates disease in a murine model of rheumatoid arthritis. Arthritis Rheum. 2013 Jun;65(6): 1477-86. 27. Yanagida M, Jung G, Tanaka Y, Sone S, Fujishiro M, Ikeda K, Nozawa K, Kaneko H, Takasaki Y, Ogawa H, Takamori K, Sekigawa I. Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor-alpha receptor. Int J Rheum Dis. 2012 Oct; 15(5): 486-95. 28. Matsushita M, Matsudaira R, Ikeda K, Nawata M, Tamura N, Takasaki Y. Anti-proteasome activator 28alpha is a novel anti-cytoplasmic antibody in patients with systemic lupus erythematosus and Sjögren's syndrome. Mod Rheumatol. 2009 Aug 14; 19(6): 622-8. 29. Brucato A, Grava C, Bortolati M, Ikeda K, Milanesi O, Cimaz R, Ramoni V, Vignati G, Martinelli S, Sadou Y, Borghi A, Tincani A, Chan EKL, Ruffatti A. Congenital heart block not associated with anti-Ro/SSA antibodies: comparison with anti-Ro/SSA positive cases. J Rheumatol. 2009 Jun 30; 36: 1744-8. 30. Nozawa K, Ikeda K, Satoh M, Reeves WH, Stewart C, Li YC, Yen TJ, Takamori K, Ogawa H, Sekigawa I, Takasaki Y, Chan EKL. Autoantibody to nuclear antigen NA14 is an independent marker primarily for Sjögren’s syndrome. Front Biosci. 2009 Jan 1; 14:3733-9. 31. Nozawa K, Fritzler MJ, Ikeda K, Takasaki Y, Satoh M, Chan EKL. Murine anti-Golgi complex autoantibody production induced by lactate dehydrogenase-elevating virus infection. Immunopharmacol Immunotoxicol. 2008 30: 13-25. 32. Jakymiw A, Pauley KM, Li S, Ikeda K, Lian S, Eystathioy T, Satoh M, Fritzler MJ, Chan EKL. The role of GW/P-bodies in RNA processing and silencing. J Cell Sci. 2007 Apr; 120(Pt 8): 1317-23. 33. Ikeda K, Satoh M, Pauley KM, Fritzler MJ, Reeves WH, Chan EKL. Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. J Immunol Methods. 2006 Dec; 20: 317(1-2):38-44. 34. Yamasaki Y, Narain S, Hernandez L, Barker T, Ikeda K, Segal MS, Richards HB, Chan EKL, Reeves WH, Satoh M. Autoantibodies to the replication protein A complex in SLE and other autoimmune diseases. Arthritis Res Ther. 2006 July; 8: R111. 35. Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EKL, Reeves WH, Satoh M. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum. 2006 Sep; 54(9): 3051-6. 36. Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EKL. Autoimmune targeting of key components of RNA interference. Arthritis Res Ther. 2006 May; 8: R87. 37. Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EKL. Relationship of maternal antibody responses to the 52kD SS-A/Ro p200 peptide and the development of fetal conduction defects. Arthritis Rheum. 2005 Oct; 52(10): 3079-86. 38. Kaneda K, Takasaki Y, Takeuchi K, Yamada H, Nawata M, Matsushita M, Matsudaira R, Ikeda K, Yamanaka K, Hashimoto H. Autoimmune response to proteins of proliferating cell nuclear antigen multiprotein complexes in patients with connective tissue diseases. J Rheumatol. 2004 Nov; 31(11): 2142-50. 39. Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, Matsudaira R, Ikeda K, Kaneda K, Hashimoto H. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2004 Nov; 14(5): 367-75. 40. Ikeda K, Takasaki Y, Hirokawa K, Takeuchi K, Hashimoto H. Clinical significance of antibodies to TS1-RNA in patients with mixed connective tissue disease. J Rheumtol. 2003 May; 30(5): 998-1005. 41. Kogure T, Takasaki Y, Takeuchi K, Yamada H, Nawata M, Ikeda K, Matsushita M, Matsudaira R, Kaneda K, Terasawa K, Hashimoto H. Autoimmune responses to proliferating cell nuclear antigen multiprotein complexes involved in cell proliferation are strongly associated with their structure and biologic function in patients with systemic lupus erythematosus. Arthritis Rheum. 2002 Nov; 46(11): 2946-56. 42. Takasaki Y, Ando S, Matsumoto K, Yamada H, Ikeda K, Nawata M, Matsushita M, Matsudaira R, Kaneda K, Takeuchi K, Tokano Y, Hashimoto H. Activated peripheral blood mononuclear cells detected in lupus patients using cDNA coding for proliferating cell nuclear antigen. Mod Rheumatol. 2002 Sep; 12(3): 239-45. 43. Hirokawa K, Takasaki Y, Takeuchi K, Kaneda K, Ikeda K, Hashimoto H. Anti-TS1-RNA: characterization of novel antibodies against sequence-specific RNA by random RNA selection in patients with Sjögren’s syndrome. J Rheumatol. 2002 May; 29(5): 931-7. 44. Nawata M, Suzuki J, Ikeda K, Ando S, Koike M, Sekigawa I, Iida N, Wada R, Matsumoto M, Oshimi K, Hashimoto H. Haemophagocytic syndrome in a systemic lupus erythematosus patient with antiphospholipid antibodies. Rheumatology (Oxford). 2001 Jul; 40(7):828-9. 45. Sekigawa I, Suzuki J, Nawata M, Ikeda K, Koike M, Iida N, Hashimoto H, Oshimi K. Haemophagocytosis in autoimmune disease. Clin Exp Rheumatol. 2001 May-Jun; 19(3): 333-8. 46. Sekigawa I, Ikeda K, Suzuki J, Nawata M, Lee S, Iida N, Hashimoto H. Novel clinical manifestations associated with antiphospholipid antibodies. Rheumatology (Oxford). 2000 Dec; 39(12): 1437-9. 47. Ikeda K, Nawata M, Ando S, Koike M, Sekigawa I, Iida N, Hashimoto H, Hirose S. Antiphospholipid antibody-associated haemophagocytic syndrome. Rheumatology (Oxford). 2000 May; 39(5): 564-5. 48. Ikeda K, Takahama M, Matsushita M, Ando S, Sekigawa I, Iida N, Hashimoto H. A case of hypopituitarism associated with antiphospholipid syndrome. Rheumatology (Oxford). 2000 Apr; 39(4): 447-8. 49. Sekigawa I, Ikeda K, Matsushita M, Ando S, Iida N, Hashimoto H. Endocrine disorders and antiphospholipid antibodies. Clin Exp Rheumatol. 2000 Mar-Apr; 18(2): 266. 50. Yamada T, Miwa H, Ikeda K, Ohta K, Iwazaki R, Miyazaki A, Watanabe S, Hashimoto H, Futagawa S, Sato N. Polyarteritis nodosa associated with gastric carcinoma and hepatitis B virus infection. J Clin Gastroenterol. 1997 Oct; 25(3): 535-7. ｢英文総説｣ 1. Ikeda K, Pauley KM, Jakymiw A, Satoh M, Fritzler MJ, Chan EKL. Autoantibodies to key components of RNA interference pathway. In: Conrad K, Chan, EKL, Fritzler MJ, Sack U, Shoenfeld Y, Wiik A (eds) From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Autoantigens, Autoantibodies and Autoimmunity. Proceedings 8th Dresden Symposium on Autoantibodies. Pabst Science Publishers, Lengerich, Germany. 2007; 168-177. 2. Takasaki Y, Kaneda K, Takeuchi K, Matsudaira R, Matsushita M, Yamada H, Nawata M, Ikeda K, Hashimoto, H. Analysis of the structure of proteasome-proliferating cell nuclear antigen (PCNA) multiprotein complex and its autoimmune response in lupus patients. Chiorazzi N, Lahita RG, Capra JD, Ferrarini M, Zabriskie JB (eds) IMMUNE MECHANISMS AND DISEASE. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2003; 987: 316-318. 3. Takasaki Y, Kaneda K, Yamada H, Ikeda K, Matsushita M, Matsudaira R, Takeuchi K, Shindo N, Murayama K, Hashimoto H: Autoimmune response to glycelaldehyde-3-phosphate dehydrogenase (GAPDH) is strongly associated with its cellular function in lupus patients. In: Conrad K, Fritzler MJ, Meurer M, Sack U, Shoenfeld Y (eds) From Proteomics to Molecular Epidemiology: Relevance of Autoantibodies. Autoantigens, Autoantibodies and Autoimmunity. Proceedings 6th Dresden Symposium on Autoantibodies. Pabst Science Publishers, Lengerich, Germany. 2002; 3: 93-115.

研究テーマ

リウマチ性疾患におけるバイオマーカー、新規治療法の探索、臨床情報管理の効率化

研究業績（論文）

「英文原著」
1. Suzuki S, Taniguchi Y, Otani T, Nakazawa T, Ikeda K, Morimoto S.
Infectious dissecting aortic aneurysm due to Streptococcus pseudopneumoniae mimicked large vessel vasculitis. Clin Case Rep Int. 2023; 7: 1545.
2. Dankers W, Northcott M, Bennett T, D’Cruz A, Sherlock R, Gearing LJ, Hertzog P, Russ B, Miceli I, Scheer S, Fujishiro M, Hayakawa K, Ikeda K, Morand EF, Jones SA.
Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ). Front. Immunol. 2022 Nov 23.
3. Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I.
Exposure of female NZBWF1 mice to imiquimod induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol. 2022 Feb 2.
4. Suzuki S, Ikeda K, Yamaji K, Tamura N, Morimoto S.
Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review. Mod Rheumatol Case Rep. 2021 Feb 9.
5. Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Kataoka Y, Suzuki S, Ikeda K, Takamori K, Yamaji K, Tamura N.
Metformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. 2021 Jul-Aug; 39(4): 763-768.
6. Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S.
Complication of COVID-19 during remission induction therapy against anti-MDA5 antibody positive dermatomyositis. Rheumatol Adv Pract. 2020 Nov 17. rkaa068.
7. Yoshida Y, Hayakawa K, Fujishiro M, Ikeda K, Tsushima H, Hirai T, Kawasaki M, Tominaga M, Suga Y, Takamori K, Sekigawa I, Morimoto S.
Social defeat stress exacerbates atopic dermatitis through downregulation of DNA methyltransferase 1 and upregulation of C–C motif chemokine receptor 7 in skin dendritic cells. Biochem Biophys Res Commun. 2020 Sep; 529(4): 1073-1079.
8. Suzuki S, Ogiwara K, Nishi T, Sakuma S, Akira M, Iwasaki M, Honda D, Takahara H, Ikeda K, Yamaji K, Tamura N, Rinno H, Morimoto S.
A Case of MPO-ANCA Positive Systemic Lupus Erythematosus Developed into Acute Kidney Injury. Arch Clin Med Case Rep. 2019 Sep; 3(6): 560-566.
9. Hayakawa K, Kawasaki M, Hirai T, Yoshida Y, Tsushima H, Fujishiro M, Ikeda K, Morimoto S, Takamori K, Sekigawa I.
MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-κB Signaling. Int. J. Mol. Sci. 2019 Feb; 20(4), 809.
10. Ikeda K, Sekiguchi N, Hirai T, Tanji K, Zushi A, Inoue M, Takasago M, Komatsu T, Morimoto S, Yamaji K, Takamori K, Tamura N, Sekigawa I.
Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patients. Musculoskeletal Care. 2018 Jun 28.
11. Niimi N, Miyashita T, Tanji K, Hirai T, Watanabe K, Ikeda K, Morimoto S, Sekigawa I.
Aortic Aneurysm as a Complication of Granulomatosis with Polyangiitis Successfully Treated with Prednisolone and Cyclophosphamide: A Case Report and Review of the Literature. Case Rep Rheumatol. 2018 Jun 5.
12. Hayakawa K, Ikeda K, Fujishiro M, Yoshida Y, Hirai T, Tsushima H, Miyashita T, Morimoto S, Suga Y, Takamori K, Ogawa H, Sekigawa I.
Connective tissue growth factor neutralization aggravates the psoriasis skin lesion: the analysis of psoriasis model mice and patients. Ann Dermatol. 2018 Feb; 30(1): 47-53.
13. Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, Morimoto S, Yamaji K, Takasaki Y, Takamori K, Tamura N, Sekigawa I.
Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen. 2018 Jan 8; 38:1.
14. Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S, Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I.
JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017 Aug 23;18(1):42.
15. Tsushima H, Morimoto S, Fujishiro M, Yoshida Y, Hayakawa K, Hirai T, Miyashita T, Ikeda K, Yamaji K, Takamori K, Takasaki Y, Sekigawa I, Tamura N.
Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity. 2017 Jul 6:1-7.
16. Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I.
Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Intern Med. 2017 May; 56(10): 1147-1152.
17. Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M, Tamura N, Sekigawa I.
Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int. 2017 Aug; 37(8): 1395-1399.
18. Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I.
The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study. Clin Rheumatol. 2017 Jan; 36(1): 51-58.
19. Uomori K, Nozawa K, Ikeda K, Doe K, Yamada Y, Yamaguchi A, Fujishiro M, Kawasaki M, Morimoto S, Takamori K, Sekigawa I, Chan EKL, Takasaki Y.
A re-evaluation of anti-NA-14 antibodies in patients with primary Sjögren's syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14. Autoimmunity. 2016 Jun 21: 1-10.
20. Miyashita T, Morimoto S, Fujishiro M, Hayakawa K, Suzuki S, Ikeda K, Miyazawa K, Morioka M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y.
Inhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis. Autoimmunity. 2015 Nov 19: 1-6.
21. Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, Sekigawa I, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N, Noguchi M.
Epstein-Barr Virus-Positive Multiple Myeloma Developing After Immunosuppressant Therapy for Rheumatoid Arthritis − A Case Report and Literature Review. Int J Clin Exp Pathol. 2015 Feb 1; 8(2): 2090-102.
22. Suzuki S, Morimoto S, Fujishiro M, Kawasaki M, Hayakawa K, Miyashita T, Ikeda K, Miyazawa K, Yanagida M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y.
Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis. Autoimmunity. 2014 Oct 29: 1-8.
23. Ikeda K, Takasaki Y, Sekigawa I.
Rapid onset of small intestinal perforation after successful steroid treatment in eosinophilic granulomatosis with polyangiitis. Mod Rheumatol. 2014 Aug 11: 1-3.
24. Doe K, Nozawa K, Hiruma K, Yamada Y, Matsuki Y, Nakano S, Ogasawara M, Nakano H, Ikeda T, Ikegami T, Fujishiro M, Kawasaki M, Ikeda K, Amano H, Morimoto S, Ogawa H, Takamori K, Sekigawa I, Takasaki Y.
Antibody against chromatin assembly factor-1 is a novel autoantibody specifically recognized in systemic lupus erythematosus. Lupus. 2014 Sep; 23(10): 1031-41.
25. Yanagida M, Kawasaki M, Fujishiro M, Miura M, Ikeda K, Nozawa K, Kaneko H, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Sekigawa I.
Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody. Biomed Res Int. 2013 (2013), 607137.
26. Nozawa K, Fujishiro M, Kawasaki M, Yamaguchi A, Ikeda K, Morimoto S, Iwabuchi K, Yanagida M, Ichinose S, Morioka M, Ogawa H, Takamori K, Takasaki Y, Sekigawa I.
Inhibition of connective tissue growth factor ameliorates disease in a murine model of rheumatoid arthritis. Arthritis Rheum. 2013 Jun;65(6): 1477-86.
27. Yanagida M, Jung G, Tanaka Y, Sone S, Fujishiro M, Ikeda K, Nozawa K, Kaneko H, Takasaki Y, Ogawa H, Takamori K, Sekigawa I.
Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor-alpha receptor. Int J Rheum Dis. 2012 Oct; 15(5): 486-95.
28. Matsushita M, Matsudaira R, Ikeda K, Nawata M, Tamura N, Takasaki Y.
Anti-proteasome activator 28alpha is a novel anti-cytoplasmic antibody in patients with systemic lupus erythematosus and Sjögren's syndrome. Mod Rheumatol. 2009 Aug 14; 19(6): 622-8.
29. Brucato A, Grava C, Bortolati M, Ikeda K, Milanesi O, Cimaz R, Ramoni V, Vignati G, Martinelli S, Sadou Y, Borghi A, Tincani A, Chan EKL, Ruffatti A.
Congenital heart block not associated with anti-Ro/SSA antibodies: comparison with anti-Ro/SSA positive cases. J Rheumatol. 2009 Jun 30; 36: 1744-8.
30. Nozawa K, Ikeda K, Satoh M, Reeves WH, Stewart C, Li YC, Yen TJ, Takamori K, Ogawa H, Sekigawa I, Takasaki Y, Chan EKL.
Autoantibody to nuclear antigen NA14 is an independent marker primarily for Sjögren’s syndrome. Front Biosci. 2009 Jan 1; 14:3733-9.
31. Nozawa K, Fritzler MJ, Ikeda K, Takasaki Y, Satoh M, Chan EKL.
Murine anti-Golgi complex autoantibody production induced by lactate dehydrogenase-elevating virus infection. Immunopharmacol Immunotoxicol. 2008 30: 13-25.
32. Jakymiw A, Pauley KM, Li S, Ikeda K, Lian S, Eystathioy T, Satoh M, Fritzler MJ, Chan EKL.
The role of GW/P-bodies in RNA processing and silencing. J Cell Sci. 2007 Apr; 120(Pt 8): 1317-23.
33. Ikeda K, Satoh M, Pauley KM, Fritzler MJ, Reeves WH, Chan EKL.
Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. J Immunol Methods. 2006 Dec; 20: 317(1-2):38-44.
34. Yamasaki Y, Narain S, Hernandez L, Barker T, Ikeda K, Segal MS, Richards HB, Chan EKL, Reeves WH, Satoh M.
Autoantibodies to the replication protein A complex in SLE and other autoimmune diseases. Arthritis Res Ther. 2006 July; 8: R111.
35. Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EKL, Reeves WH, Satoh M.
Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum. 2006 Sep; 54(9): 3051-6.
36. Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EKL.
Autoimmune targeting of key components of RNA interference. Arthritis Res Ther. 2006 May; 8: R87.
37. Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EKL.
Relationship of maternal antibody responses to the 52kD SS-A/Ro p200 peptide and the development of fetal conduction defects. Arthritis Rheum. 2005 Oct; 52(10): 3079-86.
38. Kaneda K, Takasaki Y, Takeuchi K, Yamada H, Nawata M, Matsushita M, Matsudaira R, Ikeda K, Yamanaka K, Hashimoto H.
Autoimmune response to proteins of proliferating cell nuclear antigen multiprotein complexes in patients with connective tissue diseases. J Rheumatol. 2004 Nov; 31(11): 2142-50.
39. Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, Matsudaira R, Ikeda K, Kaneda K, Hashimoto H.
Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2004 Nov; 14(5): 367-75.
40. Ikeda K, Takasaki Y, Hirokawa K, Takeuchi K, Hashimoto H.
Clinical significance of antibodies to TS1-RNA in patients with mixed connective tissue disease. J Rheumtol. 2003 May; 30(5): 998-1005.
41. Kogure T, Takasaki Y, Takeuchi K, Yamada H, Nawata M, Ikeda K, Matsushita M, Matsudaira R, Kaneda K, Terasawa K, Hashimoto H.
Autoimmune responses to proliferating cell nuclear antigen multiprotein complexes involved in cell proliferation are strongly associated with their structure and biologic function in patients with systemic lupus erythematosus. Arthritis Rheum. 2002 Nov; 46(11): 2946-56.
42. Takasaki Y, Ando S, Matsumoto K, Yamada H, Ikeda K, Nawata M, Matsushita M, Matsudaira R, Kaneda K, Takeuchi K, Tokano Y, Hashimoto H.
Activated peripheral blood mononuclear cells detected in lupus patients using cDNA coding for proliferating cell nuclear antigen. Mod Rheumatol. 2002 Sep; 12(3): 239-45.
43. Hirokawa K, Takasaki Y, Takeuchi K, Kaneda K, Ikeda K, Hashimoto H.
Anti-TS1-RNA: characterization of novel antibodies against sequence-specific RNA by random RNA selection in patients with Sjögren’s syndrome. J Rheumatol. 2002 May; 29(5): 931-7.
44. Nawata M, Suzuki J, Ikeda K, Ando S, Koike M, Sekigawa I, Iida N, Wada R, Matsumoto M, Oshimi K, Hashimoto H.
Haemophagocytic syndrome in a systemic lupus erythematosus patient with antiphospholipid antibodies. Rheumatology (Oxford). 2001 Jul; 40(7):828-9.
45. Sekigawa I, Suzuki J, Nawata M, Ikeda K, Koike M, Iida N, Hashimoto H, Oshimi K.
Haemophagocytosis in autoimmune disease. Clin Exp Rheumatol. 2001 May-Jun; 19(3): 333-8.
46. Sekigawa I, Ikeda K, Suzuki J, Nawata M, Lee S, Iida N, Hashimoto H.
Novel clinical manifestations associated with antiphospholipid antibodies. Rheumatology (Oxford). 2000 Dec; 39(12): 1437-9.
47. Ikeda K, Nawata M, Ando S, Koike M, Sekigawa I, Iida N, Hashimoto H, Hirose S.
Antiphospholipid antibody-associated haemophagocytic syndrome. Rheumatology (Oxford). 2000 May; 39(5): 564-5.
48. Ikeda K, Takahama M, Matsushita M, Ando S, Sekigawa I, Iida N, Hashimoto H.
A case of hypopituitarism associated with antiphospholipid syndrome. Rheumatology (Oxford). 2000 Apr; 39(4): 447-8.
49. Sekigawa I, Ikeda K, Matsushita M, Ando S, Iida N, Hashimoto H.
Endocrine disorders and antiphospholipid antibodies. Clin Exp Rheumatol. 2000 Mar-Apr; 18(2): 266.
50. Yamada T, Miwa H, Ikeda K, Ohta K, Iwazaki R, Miyazaki A, Watanabe S, Hashimoto H, Futagawa S, Sato N.
Polyarteritis nodosa associated with gastric carcinoma and hepatitis B virus infection. J Clin Gastroenterol. 1997 Oct; 25(3): 535-7.

｢英文総説｣
1. Ikeda K, Pauley KM, Jakymiw A, Satoh M, Fritzler MJ, Chan EKL.
Autoantibodies to key components of RNA interference pathway.
In: Conrad K, Chan, EKL, Fritzler MJ, Sack U, Shoenfeld Y, Wiik A (eds) From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Autoantigens, Autoantibodies and Autoimmunity. Proceedings 8th Dresden Symposium on Autoantibodies. Pabst Science Publishers, Lengerich, Germany. 2007; 168-177.
2. Takasaki Y, Kaneda K, Takeuchi K, Matsudaira R, Matsushita M, Yamada H, Nawata M, Ikeda K, Hashimoto, H.
Analysis of the structure of proteasome-proliferating cell nuclear antigen (PCNA) multiprotein complex and its autoimmune response in lupus patients.
Chiorazzi N, Lahita RG, Capra JD, Ferrarini M, Zabriskie JB (eds)
IMMUNE MECHANISMS AND DISEASE. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2003; 987: 316-318.
3. Takasaki Y, Kaneda K, Yamada H, Ikeda K, Matsushita M, Matsudaira R, Takeuchi K, Shindo N, Murayama K, Hashimoto H: Autoimmune response to glycelaldehyde-3-phosphate dehydrogenase (GAPDH) is strongly associated with its cellular function in lupus patients.
In: Conrad K, Fritzler MJ, Meurer M, Sack U, Shoenfeld Y (eds) From Proteomics to Molecular Epidemiology: Relevance of Autoantibodies. Autoantigens, Autoantibodies and Autoimmunity. Proceedings 6th Dresden Symposium on Autoantibodies. Pabst Science Publishers, Lengerich, Germany. 2002; 3: 93-115.

研究者

教育活動

researchmap(JST)

ホームページURL

【学校法人順天堂】研究者情報データベース

研究業績詳細

池田 圭吾（イケダ ケイゴ）

池田圭吾（イケダケイゴ）